Biologic drugs are synthesized from live organisms and are sometimes referred to as biologic response modifiers because they act by altering the manner of operation of natural intracellular and cellular actions. Some known disadvantages of biologics are that they are quite expensive to manufacture and can be quite costly for patients. They also have been found to suppress the immune system in some patients and thus increasing the risk of infections. There are some biologics that are given intravenously can cause infusion reactions in patients. On the other hand, some advantages of biologics are that they are more effective than other drugs and they have revolutionized treatments for patients who previously had no effective treatment options. For a patient suffering from psoriasis, choosing a fitting remedy can be challenging. Some medications help the patient while others exacerbate the condition. Mikhaylov et al. (2019) in their study found that the FDA approved biologic drug Ustekinumab is indeed safe and effective on psoriasis.
Biologics have acquired acclaim as safe, effective, and convenient substitutes in the healing of chronic, intermediate to harsh psoriasis. Thus, biologics have come as a great relief to patients suffering from this condition. Mourad et al. (2019) indicate that inadequacy of a drug is a major reason for discontinuing use in the long-term treatment of psoriasis. Biologics represent a significant advancement in the treatment of chronic plaque psoriasis, as evidenced by its clinical efficacy, convenience, and safety profile.
Nevertheless, there are some non-pharmacologic treatment options for psoriasis that can be carried out at home are by taking dietary supplements, applying aloe gel on the skin, avoiding perfumes and soaps that irritate the skin, also turmeric has been found to minimize flare-ups and quitting alcohol and cigarette which are triggers for psoriasis can help in managing, treating and preventing psoriasis.
References
Mikhaylov, D., Hashim, P. W., Nektalova, T., & Goldenberg, G. (2019). Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. The Journal of clinical and aesthetic dermatology, 12(6), 46–54.
Mourad, A., Straube, S., Armijo-Olivo, S., & Gniadecki, R. (2019). Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis.The British journal of dermatology, 181(3), 450–458.